Bull case
Why this leftover might be a real product question.
Adult-era CF still involves inhaled-therapy time and clinic coordination. A services or digital product with a measurable clinic workflow could sit where no therapeutic map row belongs.
Services, not a drug · N8 · Treatment burden and care delivery
H6 · Adult-era treatment-burden and care-delivery services
Opportunity Score: 62/100 · Evidence: Moderate
A clinic or operations problem, not a new medicine This card inherits the parent leftover’s score. It is not a second ranking.
Treatment burden fell and did not disappear. That is a services problem unless proven otherwise.
Not medical advice, not a recommendation to buy or sell any security, and not a claim that any opportunity should be funded.
HYPOTHESIS
A score or thesis. Always shown with evidence and a way to kill it.
Do not force a drug score onto a services problem. Clinic visits and inhaled-therapy burden remain after modulators.
FACT
A published number with a source and a date. You can check it.
Mean clinic visits were 3.0 in 2024 (4.3 in 2019). Dornase 80.6% and hypertonic saline 62.6% among ages ≥6. The Registry is 61.6% adult. Pharmacist visits were 60.4%. Telehealth mean visits were 0.4.
ANALYSIS
A filter or count this project computed, such as the reviewed CF map.
Seventeen auto-suggested active CF-like care-delivery studies exist and are not map-eligible products. N8 has zero reviewed map assets. The need scores 62/100 because commercial CF-specific services look open — not because a drug is missing.
INTERPRETATION
What we think the fact and analysis mean. Not a score yet.
Visit decline after 2019 may already be part of the solution. An empty product map plus seventeen academic behavioral studies can mean a crowded investigator space even when no company is on the grid.
Bear case
Why it might already be solved, or never be a new company.
Health systems and accredited care centers may absorb coordination as operations. Digital-health reimbursement in CF is mixed and not a claims-backed MVP input. Public Registry data do not publish minutes-per-day of therapy. Do not invent a TAM from 33,989 people.
Counterarguments
Reasons a skeptical reader would push back.
- Visit decline and telehealth may already be the residual-burden answer.
- Pharmacist visits suggest existing care-team capacity, not a missing app company.
- A services thesis that needs a CF-specific FDA path is probably a mis-specified drug thesis.
What would have to be true
Assumptions the bet needs. If these fail, the thesis fails.
A services or digital product can reduce visit burden inhaled-therapy time or adult-care coordination with a measurable CF-clinic workflow; reimbursement is plausible without inventing a TAM from 33989 people.
Kill the idea if
A pre-committed rule. If this happens, drop the thesis rather than talking yourself into it.
Kill if the only residual is clinic operations that health systems will absorb or if Registry time-use evidence never materializes.
What to check next
- Find a workflow owner (adult clinic, specialty pharmacy, or payer) before a product concept.
- Require a measurable burden endpoint; do not use Registry visit means as a market size.
- Keep this off the therapeutic competitive map.
Verdict
Services, not a drug. Keep in the investigation set. Kill if the residual is clinic operations.
This card inherits the parent need score. It is not a second ranking and not a funding recommendation.